Healx Uses AI to Accelerate Rare Disease Drug Discovery
More than 300 million people around the world live with a rare disease. Unfortunately, treatments are unavailable for most of these conditions. Developing a new medicine from scratch often takes more than 10 years and costs billions of dollars. As a result, many patients continue to wait for effective therapies.
Propel(x) portfolio company Healx is working to change this. The company combines artificial intelligence with drug repurposing to identify potential treatments faster. This approach helps reduce development time while making use of medicines that already have established safety profiles.
How Healx Uses AI for Rare Disease Drug Discovery
Healx has built an AI-powered platform that analyzes millions of medical data points. The platform searches for connections between rare diseases and existing approved medicines.
Because these medicines have already been tested for safety, researchers can often move directly to studying how well they work for a new disease. As a result, promising therapies may reach clinical trials much sooner than they would through traditional drug development.
This faster process gives researchers more opportunities to develop treatments for patients with limited or no existing options.
Recent Clinical Progress
Healx continues to expand its pipeline through clinical development, strategic collaborations, and oncology research.
Recent milestones include:
- Clinical progress for HLX-1502 in Neurofibromatosis Type 1 (NF1).
- The first patient dosed in the Phase 2 clinical trial evaluating HLX-1502 for NF1.
- A strategic collaboration with SCI Ventures to explore additional therapeutic opportunities.
- The first patient dosed in the Phase 1/2 clinical trial of HLX-4310 for metastatic recurrence in relapsed and refractory sarcoma, including osteosarcoma.
- A collaboration with the National Pediatric Cancer Foundation’s Sunshine Project™ to advance research into rare pediatric cancers.
- Expansion into additional therapeutic areas, including oncology.
Together, these milestones demonstrate the continued advancement of Healx’s AI-powered drug discovery platform.
Why Drug Repurposing Matters
Drug repurposing offers an efficient way to develop treatments for rare diseases. Instead of starting with a completely new medicine, researchers evaluate existing approved drugs for new therapeutic uses.
When combined with artificial intelligence, this strategy can help identify promising treatment candidates more quickly. It also reduces early-stage development risks and supports faster clinical evaluation.
For patients with rare diseases, every step toward a new treatment has the potential to make a meaningful difference.
A Mission to Serve Underserved Patients
Healx was co-founded by Dr. Tim Guilliams and Dr. David Brown with the goal of improving treatment options for people living with rare diseases.
By combining artificial intelligence, scientific expertise, and patient insights, the company continues to build a growing pipeline of programs focused on rare diseases and oncology.
Learn More About Healx
Register on Propelx.com to learn more about Healx and explore a curated portfolio of innovative companies developing technologies across artificial intelligence, biotechnology, healthcare, diagnostics, and other high-impact industries.
